Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.3% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 6.3% during mid-day trading on Tuesday . The company traded as high as $3.41 and last traded at $3.4550. 2,586,184 shares were traded during trading, a decline of 86% from the average daily volume of 18,141,520 shares. The stock had previously closed at $3.25.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RXRX shares. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. JPMorgan Chase & Co. reduced their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Price Performance

The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $3.30 and its two-hundred day simple moving average is $3.35. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -3.37 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the business earned ($0.41) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total value of $97,500.00. Following the completion of the sale, the director owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock valued at $478,874 over the last quarter. 6.65% of the stock is owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. NewEdge Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after buying an additional 2,428 shares during the period. Equitable Holdings Inc. raised its holdings in Recursion Pharmaceuticals by 7.1% in the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after buying an additional 2,600 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Recursion Pharmaceuticals by 1.2% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock valued at $954,000 after buying an additional 2,753 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Recursion Pharmaceuticals by 29.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after buying an additional 2,883 shares during the last quarter. Finally, Ascent Wealth Partners LLC boosted its stake in Recursion Pharmaceuticals by 11.8% during the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after buying an additional 2,974 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.